Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 13/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043850 | 0.91 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6457651 | 0.84 | NPY1R (0.42) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1593501 | 0.80 | NPY1R (0.47) | CRHR1 | |
| SCHEMBL7550723 | 0.77 | NPY1R (0.61) | ALDH1A1HPGDKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1593564 | 0.74 | CYP1A2 (0.48) | CRHR1 | |
| SCHEMBL6520712 | 0.74 | NPY1R (0.49) | CRHR1 | |
| SCHEMBL1593938 | 0.73 | NPY1R (0.46) | CRHR1 | |
| SCHEMBL1593495 | 0.72 | NPY1R (0.52) | CRHR1 | |
| SCHEMBL1593915 | 0.71 | NPY1R (0.47) | MAPTCRHR1 | |
| SCHEMBL1594081 | 0.70 | NPY1R (0.45) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | claimed |
| EP-1339819-A1 | A FABRIC SOFTENING COMPOSITION COMPRISING A MALODOR CONTROLLING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003010265-A1 | A FABRIC SOFTENING COMPOSITION COMPRISING A MALODOR CONTROLLING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-06 | — | — | WO | disclosed |
| EP-0912668-A2 | DETERGENT COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998053035-A1 | CLEAR OR TRANSLUCENT FABRIC SOFTENER COMPOSITIONS USING MIXTURE OF SOLVENTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1997043365-A2 | DETERGENT COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | ALDH1A1 2283/4885HPGD 1660/4885KDM4E 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.